|
1
|
Azizian NG, Liu Y, Pham LV, Li Y. Rational targeted therapeutics for double-hit lymphoma. Int J Hematol Oncol 2019; 8:IJH19. [PMID: 31850145 PMCID: PMC6912852 DOI: 10.2217/ijh-2019-0009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
“Double-hit lymphomas with MYC and BCL2 translocations can be effectively treated by combined targeting of the driver oncogenes”.
Collapse
Affiliation(s)
- Nancy G Azizian
- Center for Immunotherapy Research, Houston Methodist Research Institute, Houston, TX 77030, USA.,Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
| | - Yuanhui Liu
- Center for Immunotherapy Research, Houston Methodist Research Institute, Houston, TX 77030, USA.,Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
| | - Lan V Pham
- Department of Hematopathology, Division of Pathology & Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Yulin Li
- Center for Immunotherapy Research, Houston Methodist Research Institute, Houston, TX 77030, USA.,Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
| |
Collapse
|
|
2
|
Li S, Xue L, Wang M, Qiang P, Xu H, Zhang X, Kang W, You F, Xu H, Wang Y, Liu X, Yang L, Wang X. Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma. Onco Targets Ther 2019; 12:5627-5638. [PMID: 31372000 PMCID: PMC6635897 DOI: 10.2147/ott.s198567] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2018] [Accepted: 04/26/2019] [Indexed: 12/18/2022] Open
Abstract
Background: CD19-directed chimeric antigen receptor (CAR) T cells have substantial benefit in the treatment of patients with B-cell malignancies. However, despite encouraging therapeutic efficiency, there is limited overall response rate when anti-CD19 CAR-T cells are used to treat patients with relapsed and refractory (R/R) B cell lymphomas. Therefore, it further investigation is urgently needed to improve treatment efficacy. Method: A combined treatment protocol of CAR-T cell with decitabine (DAC) to treat B cell lymphoma was developed and tested on lymphoma cell lines first, and then efficacy and the underlying mechanism were investigated. After ethical approval was granted, the combined treatment protocol was applied to treat two patients with R/R B-cell lymphomas. Results: CAR-T cells were prepared successfully, and they recognized CD19 antigen expressed on lymphoma cell lines specifically. Cell-line studies also showed that CD19 antigen expression was increased by DAC pretreatment, and the function of CAR-T cells was not compromised. The cell-line study further demonstrated that lymphoma cells pretreated by DAC responded more to the treatment of CAR-T cells. Two patients with R/R B cell lymphoma were pretreated with DAC then treated with CAR-T, and both achieved complete remission (CR). Conclusions: The epigenetic modifying drug DAC increases expression of the surface antigen CD19 on lymphoma cells. The DAC pretreatment protocol may lead patients with B cell lymphoma to be more susceptible to adoptive transfer of anti-CD19 CAR-T cells treKeywordsatment.
Collapse
Affiliation(s)
- Sujun Li
- Department of Hematology of Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui, People's Republic of China
| | - Lei Xue
- Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China
| | - Min Wang
- Department of Quality Assurance, PersonGen-Anke Cellular Therapeutics Co., Ltd, China, Hefei, People's Republic of China
| | - Ping Qiang
- Department of Hematology of Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui, People's Republic of China
| | - Hui Xu
- Department of Hematology of Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui, People's Republic of China
| | - Xuhan Zhang
- Department of Hematology of Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui, People's Republic of China
| | - Wenyao Kang
- Department of Quality Assurance, PersonGen-Anke Cellular Therapeutics Co., Ltd, China, Hefei, People's Republic of China
| | - Fengtao You
- Department of Quality Assurance, PersonGen-Anke Cellular Therapeutics Co., Ltd, China, Hefei, People's Republic of China
| | - Hanying Xu
- Department of Quality Assurance, PersonGen-Anke Cellular Therapeutics Co., Ltd, China, Hefei, People's Republic of China
| | - Yu Wang
- Department of Quality Assurance, PersonGen-Anke Cellular Therapeutics Co., Ltd, China, Hefei, People's Republic of China
| | - Xin Liu
- Department of Hematology of Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui, People's Republic of China
| | - Lin Yang
- Department of Quality Assurance, PersonGen-Anke Cellular Therapeutics Co., Ltd, China, Hefei, People's Republic of China
| | - Xingbing Wang
- Department of Hematology of Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui, People's Republic of China.,Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China
| |
Collapse
|